Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $154,650.00 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 15,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $10.31, for a total value of $154,650.00. Following the completion of the transaction, the director now owns 44,623 shares in the company, valued at $460,063.13. The trade was a 25.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gilla Kaplan also recently made the following trade(s):

• On Monday, June 16th, Gilla Kaplan sold 6,814 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.38, for a total value of $70,729.32.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.31, for a total value of $309,300.00.

Tyra Biosciences Stock Down 0.9%

NASDAQ TYRA traded down $0.09 during trading on Thursday, hitting $9.50. 157,815 shares of the stock traded hands, compared to its average volume of 279,892. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60. The firm has a 50-day simple moving average of $9.70 and a 200-day simple moving average of $11.85. The company has a market capitalization of $504.36 million, a P/E ratio of -5.83 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. As a group, research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers grew its stake in shares of Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Tyra Biosciences by 5.8% during the first quarter. American Century Companies Inc. now owns 23,431 shares of the company's stock valued at $218,000 after buying an additional 1,289 shares during the last quarter. US Bancorp DE increased its stake in Tyra Biosciences by 50.5% in the first quarter. US Bancorp DE now owns 5,435 shares of the company's stock worth $51,000 after purchasing an additional 1,823 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Tyra Biosciences during the 4th quarter valued at $31,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Tyra Biosciences by 5.2% in the fourth quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock valued at $626,000 after acquiring an additional 2,221 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company's stock.

Analysts Set New Price Targets

TYRA has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush reissued an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.